AMENDED AND RESTATED SHAREHOLDERS' AGREEMENT

This amended and restated Shareholders' Agreement ("Shareholders' Agreement"), dated as of March 23, 2005 by and among NeoGenomics, Inc., a Nevada corporation having its principal offices at 12701 Commonwealth Drive, Suite 9, Fort Myers, FL 33913 (the "Company"), Michael Dent ("Dr. Dent"), Aspen Select Healthcare, LP (formerly known as MVP 3, LP), a limited partnership organized under the laws of Delaware ("ASPEN"), John Elliot, Steven Jones, and Larry Kuhnert (collectively, the "Individual Investors"). Dr. Dent, ASPEN and the Individual Investors may be referred to herein individually as a "Shareholder" and collectively as the "Shareholders." This Shareholders’ Agreement replaces and supercedes the original Shareholders’ Agreement between the parties, executed on April 15, 2003.

WHEREAS, the Shareholders own shares (the "Shares") of the issued and outstanding common stock, par value $0.001 per share (the "Common Stock") of the Company in the amounts set forth opposite their names on Schedule "A" attached to this Agreement;

WHEREAS, ASPEN, the Company and NeoGenomics, Inc., a Florida corporation and a wholly owned subsidiary of the Company, are entering into a certain Loan Agreement, dated as of March 23, 2005 (the "Loan Agreement"); and

 

WHEREAS, the Company and Shareholders believe it to be in their best interests to provide for the continuity of management and policies of the Company by imposing certain restrictions and obligations on themselves and the outstanding Shares of the Company.

NOW, THEREFORE, in consideration of the mutual promises herein set forth and subject to the terms and conditions hereof, the parties agree as follows:

 

1.1 Management and Operation of the Company. The responsibility for the overall management and operations of the Company shall be entrusted to its Board of Directors (the "Board"). The Company shall be administered in accordance with the purposes of this Agreement and in accordance with the bylaws of the Company and the laws of the State of Nevada.

1.2 Board of Directors. 

1.2.1 Number of Directors. The Shareholders agree that during the Term of this Agreement the Shareholders shall vote their Shares in favor of limiting the Board of Directors of the Company to no more than seven (7) members.

1.2.2 Election of the Board of Directors. At each annual meeting of shareholders or any special meeting of shareholders called to elect Directors, the Shareholders agree to vote their respective Shares (whether now owned or hereinafter acquired) at all such meetings of the shareholders or pursuant to any written action or consent without a meeting in favor of the following nomination and election of directors:

(i) The ASPEN Directors. Three (3) directors chosen by ASPEN (the "ASPEN Directors") to the Company's Board of Directors.

(ii) The Dent/Management Director. Dr. Dent and the Executive Management of the Company shall have the right to nominate and elect one (1) director (the "Dent/Management Director") to the Company's Board of Directors. The right of Dr. Dent and the Executive Management to appoint the Dent/Management Director will expire upon the earlier of: (i) Dr. Dent's resignation as an officer or Director of the Company; or (ii) the sale by Dr. Dent of more than fifty percent (50%) of the Shares he holds as of the date of this Agreement.

(iii) The ASPEN Independent Director. One (1) independent, non-employee director to the Company’s Board of Directors chosen by ASPEN and that is mutually acceptable to the rest of the Company’s then Board of Directors (the “ASPEN Independent Director”).

1.2.3 Non-voting Observers. At any time that less than three ASPEN Directors serve on the Company's Board of Directors, ASPEN shall be entitled to appoint a number of non-voting observers to the Board, and such observers shall be entitled to notice of and attendance at all Board meetings, advance copies of all consents provided to directors for execution, and access to all information made available to the Board. Such number of non-voting observers shall be equal to three minus the number of ASPEN Directors actually on the Board of Directors at any given time. Such observers shall incur no liability as directors for serving in their capacity as non-voting observers, but shall in their capacity as non-voting observers be eligible for indemnification by the Company to the same extent as any Board member. ASPEN shall be entitled to appoint, re-appoint, remove, replace, and fill any vacancy arising from the death, disability, resignation, or removal by ASPEN of any such observer. The Company shall not have the right to remove any such observer, but the Company shall be entitled to request that ASPEN replace any observer that the Company, in good faith, believes improperly impairs the function of the Board, to which request ASPEN shall give due consideration.

 

1.2.4 Term; etc. Dr. Dent, ASPEN and the Individual Investors shall vote their respective shares of stock for the persons nominated as directors in accordance with this Section 1.2 and who otherwise meet the standards for qualification set forth herein; provided that, notwithstanding anything else contained herein, the Shareholders shall not be required to vote their shares in favor of, and shall be entitled to remove, any director nominee who has: (i) been convicted of, or entered a plea of guilty or nolo contendere to, a felony or misdemeanor involving fraud, embezzlement, theft or dishonesty or other criminal conduct against Company, (ii) has died or been judicially declared incompetent or of unsound mind, (iii) unexcused absences from three (3) consecutive Board meetings or (iv) been terminated "for cause" (as such term is defined therein) pursuant to any written employment agreement or consulting agreement between such director and the Company. Each person nominated as a director must be at least twenty-one (21) years of age. All directors shall serve for one (1) year terms, or until their earlier death, resignation, or removal or until re-elected at any annual or special meeting of the Shareholders in accordance with the foregoing procedures and requirements of this Section. Any director of the Company may be removed with or without cause, at any time, by majority vote (or written action) of the Shareholder group who nominated and elected such director. Any vacancy on the Board of Directors shall be filled by the Shareholder group who nominated and elected such director through the holding of a special meeting of Shareholders or pursuant to a written action or consent in lieu of a special meeting.

The officers of the Company shall have such powers and duties as prescribed by the Board and the Company's bylaws and, if applicable, as set forth in such officer's employment agreement with the Company.

1.3 Capitalization. The Company represents that the current capitalization of the Company is as follows: 

(a) Common Stock: There are currently one hundred million (100,000,000) authorized shares of Common Stock, par value $.001 per share, of which 21,803,371 shares are issued and outstanding.

(b) On a Fully-Diluted Basis: Except for (i) unexercised employee options and stock awards totaling 1,782,329 shares under the Company’s 2003 Equity Incentive Plan, (ii) 650,000 options that the Company intends to issue to two new officers of the Company once the option plan has been amended, and (iii) warrants to acquire 171,800 shares at $0.01/share that have been awarded to two consultants of the Company, and (iv) warrants to acquire up to 250,000 shares at $0.25/share based on meeting certain performance milestones, which the Company issued to a consultant, there are not outstanding any options, warrants, rights (including conversion or preemptive rights), or agreements for the purchase or acquisition from the Company or, to the knowledge of the Company from any shareholder, of any shares of the capital stock of the Company.

 

 

2.1 Restrictions on Sales of Stock by Shareholders

 

(a) Subject to Section 2.1(b), the Shareholders shall not sell, assign, transfer, convey or otherwise dispose of (a "Sale") any of their Shares, whether now owned or hereafter acquired, unless they have complied with the provisions of Section 2.2 hereof (in the case of Dr. Dent) and then, to the extent applicable, with the provisions of Sections 2.3 and/or 2.4 hereof.

 

(b) Any Sale or attempted Sale of Stock in violation of any provision of this Agreement shall be void, and the Company shall not record such Sale on its books or treat any purported transferee of such Stock as the owner of such Stock for any purpose.

 

2.2  Rights of First Offer. Subject to Section 2.2(f), in addition to and not in limitation of any other restrictions on Sales of Shares contained in this Agreement, any Sale of Stock by Dr. Dent shall be consummated only in accordance with the following procedures:

 

(a) Dr. Dent shall first deliver to the Company and the Individual Investors a written notice (a "RFR Offer Notice"), which shall (i) state Dr. Dent's intention to sell Shares to one or more persons, the amount and type of Shares to be sold (the "Subject Shares"), the purchase price therefor and a summary of the other material terms of the proposed Sale and (ii) offer the Company and the Individual Investors the option to acquire all or a portion of such Subject Shares upon the terms and subject to the conditions of the proposed Sale as set forth in the RFR Offer Notice (the "RFR Offer"), provided that such RFR Offer may provide that it must be accepted by the Company and the Individual Investors (in the aggregate) on an all or nothing basis (an "All or Nothing Sale"). The RFR Offer shall remain open and irrevocable for the periods set forth below (and, to the extent the RFR Offer is accepted during such periods, until the consummation of the Sale contemplated by the RFR Offer). The Company shall have the right and option, for a period of 15 days after delivery of the RFR Offer Notice (the "Company RFR Acceptance Period"), to accept all or any part of the Subject Shares at the purchase price and on the terms stated in the RFR Offer Notice, provided that the Company may accept less than all of the Subject Shares, in an All or Nothing Sale, only if all of the remaining Subject Shares is accepted by the Individual Investors as set forth below. Such acceptance shall be made by delivering a written notice to Dr. Dent and to each of the Individual Investors within the Company RFR Acceptance Period.

 

(b) If the Company shall fail to accept all of the Subject Shares offered for Sale pursuant to, or shall reject in writing, the RFR Offer (the Company being required to notify in writing Dr. Dent and each of the Individual Investors of its rejection or failure to accept in the event of the same), then, upon the earlier of the expiration of the Company RFR Acceptance Period or the giving of such written notice of rejection or failure to accept such offer by the Company, each Investor shall have the right and option, for a period of 30 days thereafter (the "Individual Investors RFR Acceptance Period"), to accept all or any part of the Subject Shares so offered and not accepted by the Company (the "Refused Stock") at the purchase price and on the terms stated in the RFR Offer Notice; provided, however, that, if the RFR Offer contemplated an All or Nothing Sale, the Individual Investors, in the aggregate, may accept, during the Investor RFR Acceptance Period, all, but not less than all, of the Refused Stock, at the purchase price and on the terms stated in the RFR Offer Notice. Such acceptance shall be made by delivering a written notice to the Company and Dr. Dent within the Individual Investors RFR Acceptance Period specifying the maximum number of shares such Investor will purchase (the "First Offer Shares"). If, upon the expiration of the Individual Investors RFR Acceptance Period, the aggregate amount of First Offer Shares exceeds the amount of Refused Stock, the Refused Stock shall be allocated among the Individual Investors in proportion to their ownership of the Company's capital stock on a fully diluted basis.

 

(c) If effective acceptance shall not be received pursuant to Sections 2.2(a) and/or 2.2(b) above, within the periods specified above, with respect to all of the Subject Shares offered for Sale pursuant to the RFR Offer Notice, then Dr. Dent may sell all or any portion of the Shares so offered for Sale and not so accepted (or, in the case of an All or Nothing Sale, all of the Subject Shares offered for sale pursuant to the RFR Offer Notice), at a price not less than the price, and on terms not more favorable to the purchaser thereof than the terms, stated in the RFR Offer Notice at any time within 90 days after the expiration of the Individual Investors RFR Acceptance Period (the "Sale Period"). To the extent Dr. Dent Sells all or any portion of the Shares so offered for Sale during the Sale Period, Dr. Dent shall promptly notify the Company, and the Company shall promptly notify the Individual Investors, as to (i) the number of Shares, if any, that Dr. Dent then owns, (ii) the number of Shares that Dr. Dent has sold, (iii) the terms of such Sale and (iv) the name of the owner(s) of any shares of Shares sold. In the event that all of the Shares are not sold by Dr. Dent during the Sale Period, the right of Dr. Dent to sell such unsold Stock shall expire and the obligations of this Section 2.2 shall be reinstated.

 

(d) All Sales of Subject Shares to the Company and/or the Individual Investors subject to any one RFR Offer Notice shall be consummated contemporaneously at the offices of the Company on a mutually satisfactory business day within 30 days after the expiration of the Company RFR Acceptance Period or the Investor RFR Acceptance Period, as applicable, or such other time and/or place as the parties to such Sales may agree. The delivery of certificates or other instruments evidencing such Subject Shares duly endorsed for transfer shall be made on such date against payment of the purchase price for such Subject Shares.

 

(e) Anything contained herein to the contrary notwithstanding, prior to any Sale of Shares by Dr. Dent pursuant to this Section 2.2, Dr. Dent shall, after complying with the provisions of this Section 2.2, comply with the provisions of Sections 2.3 and 2.4 hereof, in each case as applicable.

 

(f) Notwithstanding the provisions of Sections 2.2(a), (b) and (c), in the event that Dr. Dent shall propose to sell his Shares pursuant to provisions of Rule 144, Dr. Dent shall first deliver to the Company and the Individual Investors, a written notice (a "RFR Offer Notice"), which shall (1) state that Dr. Dent intends to sell Shares pursuant to Rule 144, including the number of shares proposed to be sold (the "Subject Shares") and (ii) offer the Company and the Individual Investors the option to acquire all or any portion of any such Shares at the market price for the Shares on the date of such notice (the "RFR Offer"). The RFR Offer shall remain open and irrevocable for the periods set forth below. The Company shall have the right and option for a period of ten days after delivery of the RFR Offer Notice, to accept all or any part of the Subject Shares at the purchase price described in the RFR Offer Notice. Such acceptance shall be made by delivering written notice to Dr. Dent and to each of the Individual Investors within the required period. If the Company shall fail to accept all of the Subject Shares offered for sale pursuant to the RFR Offer, then upon the expiration of the Company's acceptance period, each Individual Investor shall have the right and option, for a period of ten days thereafter, to accept all or any part of the Subject Shares so offered and not accepted by the Company at the purchase price described in the RFR Offer Notice. Such acceptance shall be made by delivering written notice to the Company and Dr. Dent within the required period specifying the maximum number of shares each such shareholder desires to purchase. If, the number of available shares exceeds the number available, the available number shall be allocated among the Individual Investors in proportion of their ownership of the Company's capital stock on a fully diluted basis. If the Company and the Individual Investors do not agree to purchase all of the Subject Shares offered for sale pursuant to the RFR Offer Notice within the time periods set forth above, Dr. Dent may sell all or any portion of the Subject Shares not purchased into the existing current public market, at such price as he may receive in the public market, for a period of 90 days after the expiration of the Individual Investor's rights. To the extent Dr. Dent sells all or any portion of the Subject Shares, Dr. Dent shall promptly notify the Company and the Company shall promptly notify the Individual Investors as to the number of Subject Shares which Dr. Dent has sold pursuant to this provision. In the event that all of the Subject Shares are not sold by Dr. Dent during this 90 day period, the right of Dr. Dent to sell such unsold Shares shall expire and the obligations of this Section 2.2 shall be reinstated as to such Shares.

2.3 Right of Co-Sale.

(a) If any Shareholder (an "RCS Selling Shareholder") proposes to sell any Shares ("Co-Sale Shares") to a party or group (a "Co-Sale Transferee") in a transaction or series of related transactions resulting in the Co-Sale Transferee for the first time controlling the power to vote more than 25% of the total votes for nominees to the Board, such RCS Selling Shareholder shall first give reasonable notice in reasonable detail to each other Shareholder in sufficient time to allow each other Shareholder to participate in the sale on the same terms and conditions as such RCS Selling Shareholder. To the extent any prospective Co-Sale Transferee(s) refuses to purchase shares or other securities from a Shareholder exercising its rights of co-sale hereunder, the RCS Selling Shareholder shall not sell to such prospective Co-Sale Transferee(s) any co-Sale Shares unless and until, simultaneously with such sale, the RCS Selling Shareholder shall purchase the offered shares or other securities from the other Shareholder. Notwithstanding the foregoing, this Section 2.2(a) shall not apply to (i) any pledge of Co-Sale Shares made pursuant to a bona fide loan transaction that creates a mere security interest; (ii) any transfer to the ancestors, descendants or spouse or to trusts for the benefit of such persons of a transferring Shareholder; (iii) any bona fide gift; provided that the transferring Shareholder shall inform the other Shareholders of such pledge, transfer or gift prior to effecting it; or (iv) any sale of Shares pursuant to Rule 144. Such transferred Co-Sale Shares will remain "Co-Sale Shares" hereunder, and such pledgee, transferee or donee shall be bound by the terms and provisions of this Agreement.

 

2.4 Drag-Along Rights.

(a) If at any time the Shareholders holding fifty percent or more of the Company's then outstanding shares of capital stock (the "DAR Selling Shareholders(s)") shall propose to undertake a sale of fifty percent (50%) or more of the Company's then issued and outstanding shares of capital stock to an unaffiliated third party or group in a single transaction or series of related transactions (a "Proposed Drag-Along Transaction"), then each Shareholder shall, if requested by such DAR Selling Shareholder(s), sell all of its Shares in such transaction on the same terms and for the same per Share consideration. Such DAR Selling Shareholder(s) shall give each other Shareholder written notice ("Drag-Along Notice") of any Proposed Drag-Along Transaction at least twenty (20) days prior to the date on which such Proposed Drag-Along Transaction shall be consummated, including the terms and conditions thereof, and each such other Shareholder shall have the obligation to sell its Shares on such same terms and conditions in accordance with the instructions set forth in such Drag-Along Notice. In such event, each Shareholder shall deliver the Share certificate(s) (accompanied by duly executed stock powers or other instrument of transfer duly endorsed in blank) representing the Shares to the Company or to an agent designated by the Company for the purpose of effectuating the transfer of the Shares to the purchaser and the disbursement of the proceeds of such transactions to the Shareholder(s).

(b) Without limiting the generality of the foregoing, if the DAR Shareholders approve a sale (an "Approved Sale") structured as a merger or a consolidation or a sale of assets, then each Shareholder shall, if requested by the Company (i) vote for, consent to and/or not raise objections against such Approved Sale, (ii) waive (to the extent applicable) any dissenters, appraisal rights or similar rights in connection with a merger or consolidation, and (iii) take all necessary and desirable actions in connection with the consummation of the Approved Sale as reasonably requested by the Company, including, without limitation, exercising any warrants or conversion privileges.

(c) Any Shareholder required by the provisions of this Article II to transfer Shares shall not be required to make any representations and warranties in connection with such transfer or sale except as to good title and the absence of liens with respect to such Shares, the corporate or other existence of the Shareholder and the authority, form, validity and binding effect of, and the absence of any conflicts under the charter documents and material agreements of such Shareholder. No such Shareholder shall be required to provide any indemnity in connection with such Approved Sale except for indemnities for damages resulting from a breach of the above-stated representations and warranties.

3.1. Preemptive Rights.

 

(a) Except for the transactions identified on Schedule 3.1, The Company hereby grants to each Shareholder, for a period of two (2) years from the date hereof, a preemptive right to purchase, on a pro rata basis and at the same price and upon the same terms as any other investors at such time, all or any part of any New Securities (as defined below) which the Company may, from time to time, propose to sell and issue subject to the terms and conditions set forth below. A Shareholder's pro rata share, for purposes of this subsection (a), shall equal a fraction, the numerator of which is the number of shares of Common Stock then held by such Shareholder on a fully-diluted basis, and the denominator of which is the total number of shares of Shares then held by all of the Shareholders on a fully-diluted basis.

 

(b) "New Securities" shall mean any capital stock of the Company whether now authorized or not and rights, options or warrants to purchase capital stock, and securities of any type whatsoever which are, or may become, convertible into capital stock; provided, however, that the term "New Securities" shall expressly not include (i) securities offered to the public pursuant to a Public Offering; (ii) securities issued for the acquisition of another corporation by the Company by merger, purchase of substantially all the assets of such corporation or other reorganization resulting in the ownership by the Company of not less than 51% of the voting power of such corporation; (iii) Common Stock issued to employees or consultants of the Company pursuant to a stock option plan, employee stock purchase plan, restricted stock plan or other employee stock plan or agreement approved by the Board of Directors of the Company (provided that the total number of shares to be issued under all such plans does not exceed 12.5% of the Company's shares outstanding as of the date of this Agreement); or (iv) securities issued as a result of any stock split, stock dividend or reclassification of Common Stock, distributable on a pro rata basis to all holders of Common Stock.

 

(c) If the Company intends to issue New Securities, it shall give each Shareholder ten (10) days written notice of such intention, describing the type of New Securities to be issued, the price thereof and the general terms upon which the Company proposes to effect such issuance. Each Shareholder shall have thirty (30) days (the "Exercise Period") from the date of any such notice to agree to exercise its preemptive right by giving written notice to the Company stating the quantity of New Securities to be so purchased. Each Shareholder shall have a right of overallotment such that if any Shareholder fails to exercise his or its preemptive right hereunder, the other Shareholders may purchase such portion on a pro rata basis, by giving written notice to the Company within ten (10) days from the date that the Company provides written notice to the other Shareholders of the amount of New Securities with respect to which such nonpurchasing Shareholder has failed to exercise its or his right hereunder.

 

(d) If any Shareholder or Shareholders fail to exercise the foregoing preemptive right with respect to any New Securities within the Exercise Period (or the additional ten day period provided for overallotments), the Company may thereafter sell any or all of such New Securities not agreed to be purchased by the Shareholders, at a price and upon general terms no more favorable to the purchasers thereof than specified in the notice given to each Shareholder pursuant to paragraph (c) above. In the event the Company has not sold such New Securities within a ninety (90) day period following expiration of the Exercise Period, the Company shall not thereafter issue or sell any New Securities without first offering such New Securities to the Shareholders in the manner provided above.

 

 

4.1 Dealings with Affiliates. The Company and its subsidiaries will not enter into any transaction with ASPEN, the Individual Investors, Dr. Dent or their affiliates, or any other officer or director of the Company or its subsidiaries, or any member of their respective immediate families or any corporation or other entity directly or indirectly controlled by one or more of such persons or members of their immediate families, except for transactions made for valid business purposes on terms and conditions which the independent directors of the Company conclude are reasonable and arm's length. When there are no independent directors on the Board, the members of the Board of Directors that do not have an interest in any such transaction being evaluated, will make such determination; including the transaction currently being contemplated whereby NeoGenomics will become the first customer of HCSS, LLC’s small laboratory network. As described on Schedule 4.1, HCSS, LLC is a company co-owned by Dr. Dent and eTelenext, Inc.

4.2 Indemnification. 

(a) The Company agrees that, except as may be limited by applicable law, for six years from and after the date of this Agreement, the indemnification obligations set forth in the Company's bylaws as of the date of this Agreement, will not be amended, repealed or otherwise modified in any manner that would adversely affect the rights thereunder of the individuals who on or at any time prior to the date of this Agreement were entitled to indemnification thereunder with respect to matters occurring prior to the date of this Agreement.

(b) In addition to, and not in lieu of the forgoing, the Company shall indemnify, defend and hold harmless all officers and directors of the Company as of the date of this Agreement (the "Indemnified Parties") to the fullest extent permitted by applicable law and in the bylaws of the Company, as in effect as of the date hereof, from and against all liabilities, costs, expenses and claims (including, without limitation reasonable legal fees and disbursements, which shall be paid, reimbursed or advanced by the Company in a manner consistent with the applicable provisions of the Company's bylaws) arising out of actions taken prior to the date of this Agreement in performance of their duties as directors and officers of the Company, in connection with the transactions contemplated by this Agreement, which may be asserted against the Indemnified Parties from and after the date of this Agreement, provided, however, that the Company shall not have the obligation hereunder to any Indemnified Party if the indemnification of such Indemnified Party in the manner contemplated hereby is determined pursuant to a final non-appealable judgment rendered by a court of competent jurisdiction to be prohibited by applicable law.

5.1. Specific Performance. Since it is impossible to measure in money the damages which would accrue by reason of a party's failure to perform any of its or his obligations under this Agreement. It is agreed that the parties hereto would be irreparably damaged in the event that this Agreement were not specifically enforced. Should, therefore, any dispute arise concerning the sale or disposition of any Shares, an injunction may be issued restraining the sale or disposition of such Shares pending the termination of such controversy. The purchase or sale of any Shares shall also be enforceable by a decree of specific performance. Such remedies shall not be exclusive, but shall be in addition to any other rights or remedies which the parties may have at law or in equity.

5.2. Termination. This Agreement shall automatically terminate upon the occurrence of any one of the following events:

(a) Cessation of the Company's business;

 

(b) Bankruptcy, receivership, or dissolution of the Company;

(c) Voluntary agreement in writing among the Company and each of the Shareholders; or

(d) The Company's completion of a public offering of its equity securities in which the gross proceeds to the Company are at least $10,000,000.

 

5.3 Legend. Each Shareholder and the Company shall take all action necessary (including exchanging with the Company certificates representing Shares issued prior to the date hereof) to cause each certificate representing outstanding Shares to bear a legend containing the following words:

 

 

5.4. Notices. Any and all notices or other communications required or permitted to be given hereunder shall be given in writing by certified mail, return receipt requested, addressed in the case of the Company to its principal office, and in the case of a Shareholder to his address appearing on the stock books of the Company and, if to the Individual Investors, with a copy to:

 

115 East 57^th Street, Suite 1006

New York, New York 10022

Phone: (646) 486-9772

Telecopier No.: (646) 486-9771

Attn.: Michael Membrado, Esq.

5.5. Partial Invalidity. If any portion of this Agreement shall be ruled or adjudicated invalid for any reason, that portion shall be deemed excised here from and the remainder of this Agreement shall continue in full force and effect unaffected by any such invalidity.

5.6. Benefit and Binding Effect. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective heirs, legal representatives, successors and assigns. In the event that a Shareholder transfers any of its Shares to a third party, then, as a condition to such transfer, the third party shall enter into a counterpart of this Agreement and shall have all of the rights, and be subject to all of the duties and restrictions of a Shareholder under this Agreement, provided, however, that a transferee will not become a party to this Agreement, nor be subject to the duties and restrictions imposed on the Shareholders under this Agreement, if the transferee acquires the Shares in any of the following transfers:

(a)

the previous sale of MVP 3 of 400,000 shares where this requirement is now waived;

(b)

the previous transfer by Steven Jones of 366,666 to two trusts for the benefit of his Children;

(c)

a sale of any Shares pursuant to Rule 144;

(d)

a sale pursuant to Section 2.4.;

(e)

a sale by ASPEN of any of the 1,650,000 shares that ASPEN has granted or intends to grant an option upon; or

(f)

an offering registered under the Securities Act of 1933, as amended.

Notwithstanding anything to the contrary contained in this Agreement, during the period between the date of this Agreement and March 31, 2007, Dr. Dent, for as long as he is either an Officer or Director, shall not transfer in excess of 500,000 Shares during any calendar year, unless (i) as a condition to such transfer, the third party receiving shares in excess of 500,000 during any such calendar year shall enter into a counterpart of this Agreement and shall have all of the rights, and be subject to all of the duties and restrictions of a Shareholder under this Agreement, or (ii) such transfer is made pursuant to Section 2.3 (Right of Co-Sale) hereof.

5.7. Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed to be an original, and it shall not be necessary in making proof of this Agreement to produce or account for more than one such counterpart.

5.8. Governing Law. The corporate laws of the State of Nevada shall govern all issues concerning the relative rights of the Company and its shareholders. All other questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of Florida, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Florida or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State Florida. Each party hereby irrevocably submits to the jurisdiction of the Circuit Court for Collier County, Florida and the United States District Court for the Middle District of Florida, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

5.9 Entire Agreement. Each party hereto acknowledges that it or he has read this Agreement, understands it, and agrees to be bound by its terms, and further acknowledges and agrees that it is the complete and exclusive statement of the agreement and understanding of the parties regarding the subject matter hereof, which supersedes and merges all prior proposals, agreements and understandings, oral and written, relating to the subject matter hereof. This Agreement may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension or discharge is sought.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

	NEOGENOMICS, INC.
	By:	/s/Robert Gasparini
	Name:   Robert Gasparini
	Title:    President
	ASPEN SELECT HEALTHCARE, LP (Formerly Known as MVP 3, LP), a Delaware limited partnership
	By:	Medical Venture Partners, LLC, a Delaware limited liability company, its General partner
	By:	/s/Steven C. Jones
	Name:  Steven C. Jones
	Title:    Member
	/s/Michael T. Dent, M.D.
	Michael T. Dent, M.D.
	/s/John Elliot
	John Elliot
	/s/Steven Jones
	Steven Jones
	/s/Larry Kuhnert
	Larry Kuhnert

 

Name		Number of Shares
Aspen Select Healthcare, LP			9,903,279	(1)
John Elliot			1,041,261	(2)
Steven Jones			1,174,595	(3)
Larry Kuhnert			1,041,261	(4)
Michael Dent			2,490,634	(5)

(1) 9,303,279 shares originally purchases plus 1,000,000 shares purchased on 3/21/05 from John Elliott and Larry Kuhnert minus 400,000 shares sold.

(2) 1,541,261 shares originally purchased minus 500,000 shares sold to Aspen Select Healthcare, LP on 3/21/05.

(3) 1,541,261 shares originally purchased minus 500,000 shares sold to Aspen Select Healthcare, LP on 3/21/05.

 

(4) 1,541,261 shares originally purchased minus 366,666 shares transferred to two trusts for the benefit of Mr. Jones’s children.

(5) 2,385,000 original founders’ shares plus 105,634 shares issued in connection with services.

Schedule 4.1; NeoGenomics has entered into an agreement dated March 11, 2005 with HCSS, LLC to provide eTelenext Accessioning Application, AP Anywhere Application and CMQ Application. HCSS, LLC is a holding company created to build a small laboratory network for the 50 small commercial genetics laboratories in the United States. The opportunity that exists is that the small laboratories are too small to afford an elaborate laboratory information system (LIS) but are all in need of one. Each laboratory would be required to pay $152,000 in license fees plus monthly ASP service and Maintenance support fees to go direct to eTeleNext. Also the productivity of technologists in small laboratories is difficult to maintain year round and the small laboratory network will allow small laboratories to better utilize their staffing levels when business is busy or slow. Joseph Nollar, the owner of eTeleNext has invested the LIS applications with total license fees of $152,000 to be co-owner of HCSS, LLC. NeoGenomics signing up as the first customer of HCSS,LLC saves the company $152,000 in license fees and gets access to the much needed LIS system immediately (within 12 weeks for installation). NeoGenomics only pays the monthly ASP service and maintenance fee and a membership fee of $6,000 per year and a monthly per test fee ranging from $10 for the first 50 tests to $2.50 per test from 150 – 1000 tests per month. The current ownership structure is Dr. Dent owns 66.7% of HCSS, LLC and eTeleNext owns 33.3%.